Subscribe
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma
Articles
Articles
Novel CAR-T Therapy Shows Impressive Results in Aggressive Leukemia, Lymphoma
By
Phoebe Starr
Leukemia
,
Lymphoma
,
Personalized Medicine
February 2014, Vol 5, No 1
New Orleans, LA—Mounting evidence from several research centers shows that autologous T-cells genetically engineered with a chimeric antigen receptor-T (CAR-T; also called CTL019) achieve dramatic responses in patients with advanced leukemia and lymphoma who have exhausted all treatment options.
Read More
ASCO Proposes New Reimbursement Model by Medicare for Cancer Care
By
Neil Canavan
Economics & Value
,
Economics of Cancer Care
February 2014, Vol 5, No 1
The American Society of Clinical Oncology (ASCO) has proposed a radical new model for the reimbursement of oncology services under Medicare, with the new paradigm consisting of incentives for oncologists to emphasize quality rather than quantity of care as the greater good to the bottom line.
Read More
Hispanics More Likely than Caucasians to Develop Major Complications after Radical Cystectomy
By
Rosemary Frei, MSc
Bladder Cancer
November 2013, Vol 4, No 9
Vancouver, Canada—The odds of having a major complication after a radical cystectomy, which is performed as part of the treatment for bladder cancer, are higher for Hispanics than for Caucasians, researchers have found. They calculated that the rate of such complications was 23.53% for Hispanic Americans compared with 16.09% for Caucasian Americans.
Read More
The Cost of End-of-Life Care in Oncology
By
Craig Deligdish, MD
End-of-Life Care
,
From the Editor
,
Policies & Guidelines
,
Value Peer-spectives
November 2013, Vol 4, No 9
The recent Institute of Medicine report “Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis” addressed the important issues of delivering high-quality cancer care, including end-of-life care.
Read More
Sulfasalazine Fails to Prevent Radiotherapy-Induced Diarrhea
By
Charles Bankhead
Radiotherapy in Focus
,
Personalized Medicine
November 2013, Vol 4, No 9
Atlanta, GA—Patients with cancer treated with pelvic radiation did not have fewer bouts of diarrhea when treated prophylactically with the anti-inflammatory drug sulfasalazine (Azulfidine), a randomized trial showed. Patients receiving sulfasalazine had radiation-associated severe diarrhea almost 3 times as often as patients receiving placebo.
Read More
Expanded Radiotherapy Improves Breast Cancer Control
By
Charles Bankhead
Radiotherapy in Focus
,
Personalized Medicine
November 2013, Vol 4, No 9
Amsterdam, The Netherlands—Expanded radiotherapy led to significantly better disease-free survival (DFS) and metastasis-free survival (MFS) rates in women with early breast cancer, according to the results of a large study reported at the European Cancer Congress 2013.
Read More
Ten Steps to Achieving Value-Based Care at the Mayo Clinic
By
Rosemary Frei, MSc
Value in Oncology
,
Value-Based Care
November 2013, Vol 4, No 9
Phoenix, AZ—The staff at the Mayo Clinic are working to “bend the cost curve” and optimize resource utilization efficiency while continuing to provide high-quality care to their large population of patients, said Kari Bunkers, MD, Chief Medical Information Officer, Mayo Clinic Health System, and Medical Director, Mayo Clinic Office of Population Health Management (OPHM) at the American Medical Group Association 2013 Institute for Quality Leadership conference.
Read More
Physician-Focused Improvement in Patient Satisfaction at the Cleveland Clinic
By
Rosemary Frei, MSc
Patient Communication
,
Value Peer-spectives
November 2013, Vol 4, No 9
>Phoenix, AZ—The degree of patient satisfaction with healthcare is becoming paramount in the new era of value-based care, according to James Merlino, MD, Chief Experience Officer, and Associate Chief of Staff, Patient Experience Office, Cleveland Clinic Health System (CCHS), OH, who discussed high-value healthcare at the American Medical Group Association 2013 Institute for Quality Leadership conference.
Read More
Oral VEGF Inhibitor, Cediranib, Improves Survival in Recurrent Ovarian Cancer
By
Charles Bankhead
Ovarian Cancer
November 2013, Vol 4, No 9
Treatment with the oral angiogenesis inhibitor cediranib led to significant improvements in overall survival (OS) and progression-free survival (PFS) in patients with recurrent ovarian cancer, according to new data reported at the European Cancer Congress 2013.
Read More
Gilotrif: Second-Generation Tyrosine Kinase Inhibitor Indicated for the First-Line Treatment of Patients with Non–Small-Cell Lung Cancer and EGFR Mutation
By
Lisa A. Raedler, PhD, RPh
Drug Updates
November 2013, Vol 4, No 9
Read More
Page 244 of 329
241
242
243
244
245
246
247
Top Trending Articles
1.
ACCC Federal Policy Update Highlights Key Risks and Opportunities for Oncology Practices in 2026
Meg Barbor, MPH
2.
From Chaos to Clarity: Data-Driven Denial Prevention
Shawntea (Taya) Gordon, MBA, FACMPE
3.
The Evolving Landscape of Lung Cancer Care
Meg Barbor, MPH
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma